PER

2.50%

8.2¢ percheron therapeutics limited

As soon as we get the results in for SCM, we should ask Mark the...

First 2 Last

Share
Profile

Follow
cgt2009

13,950 Posts.

131

17/06/14

14:17

Post #: 13534654
Share

Originally posted by zoomyjeff ↑

With Stem Cell information very very Close I would expect a gradual rise. Contrary to Monti I would not expect much pre Financial year selling, there has not been enough significant change in the past year to make it worthwhile selling to balance your tax. Apart from that there is a large majority like myself in 12 month Capital gains territory and until ANP returns a significant gain on investment I cannot see any of us selling.

One for CGT, in the event of significant gains both on its own and combined with
Granulocyte Colony Stimulating Factor (G-CSF), how long would you anticipate commercialisation?

Below are details of the March news which indicates mid year news:

Antisense Therapeutics Limited CEO and Managing Director Mark Diamond said “The stem cell
mobilisation opportunity for ATL1102 while commercially attractive with, by our estimation, a market
potential of several hundred million dollars per annum, also presents as an excellent return on
investment proposition given costs are expected to be relatively low for developing the drug in this
indication. We believe that positive outcomes from this trial will strongly enhance our drug’s potential
for this application and naturally we relish the opportunity to further develop a drug that can
potentially provide better outcomes for cancer patients. We look forward to successfully conducting
the study and to reporting results from this SCM trial which are anticipated mid-year.”

Expand

As soon as we get the results in for SCM, we should ask Mark the question about timelines. My memory is hopeless but I do recall some SCM P2 & P3 trials being shortish while most being quite long. I'm hoping Mark has a cunning plan to expedite the process. However its all moot if the P1 is a duster. Tick. Tock.

ANP Price at posting: 14.0¢ Sentiment: Buy Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

SBW

Shekel Brainweigh investor presentation webinar – the future of retail automation

As Nvidia cools, we're looking to Aussie AI

CBA breaks trading record on strong day for Aussie financials

BIT

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

PRU

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

OCC

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

LAM

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

RMX

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

QML

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

There are more pages in this discussion • 65 more messages in this thread...

First 2 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.2¢		Change 0.002(2.50%)		Mkt cap ! $73.92M

Open	High	Low	Value	Volume
8.0¢	8.2¢	7.9¢	$16.80K	210.0K

Buyers (Bids)

No.	Vol.	Price($)
1	24999	7.9¢

Sellers (Offers)

Price($)	Vol.	No.
8.3¢	31992	1

View Market Depth

No.	Vol.	Price($)
1	24999	0.079
2	60000	0.078
2	114144	0.077
2	46800	0.075
1	100000	0.074

Price($)	Vol.	No.
0.083	31992	1
0.084	100000	1
0.085	136669	3
0.086	33375	2
0.087	531562	3

Last trade - 16.10pm 06/09/2024 (20 minute delay)

PER (ASX) Chart

As soon as we get the results in for SCM, we should ask Mark the...

Shekel Brainweigh investor presentation webinar – the future of retail automation

As Nvidia cools, we're looking to Aussie AI

CBA breaks trading record on strong day for Aussie financials

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

As soon as we get the results in for SCM, we should ask Mark the...

Top Stories

Shekel Brainweigh investor presentation webinar – the future of retail automation

As Nvidia cools, we're looking to Aussie AI

CBA breaks trading record on strong day for Aussie financials

HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo

Perseus Mining boosts stake in Predictive Discovery to 19.9% as latter's flagship project stalls

Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil

Laramide sniffs prime Kazakh uranium, with agreement over 6000 square km land position

Red Mountain Mining: record gold prices, two projects, two greenstone belts

Week 36 Wrap: AI hype wave tested again; Oz per capita recession continues; AirTrunk’s $40B+ payday

Metallurgical testing shows saleable copper and pyrite from QMines' Develin Creek project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News